The company has received EIR from the United States Food and Drug Administration (USFDA) for the inspection conducted at the Halol facility during the period February 12-23, 2018, Sun Pharma said in a filing to BSE.
"The agency concluded that the inspection is now closed and the issues contained in the warning letter issued in December 2015 have been addressed," it added.
Commenting on the development, Sun Pharma MD Dilip Shanghvi said, "This is an important development for Sun Pharma. We remain committed to following the highest levels of quality and 24x7 cGMP compliance at all our manufacturing facilities globally."
In February, the USFDA had issued three observations after inspecting the facility. The company had said it was preparing the response to the observations.
This followed inspection of the facility in September 2014 by FDA inspectors.
Shares of Sun Pharmaceutical Industries today closed at Rs 540.50 per scrip on BSE, up 1.03 per cent from its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)